Document Detail

Frequent downregulation of Fas (CD95) expression and function in melanoma.
MedLine Citation:
PMID:  12140383     Owner:  NLM     Status:  MEDLINE    
Membrane-bound Fas ligand (FasL, Apo-1L, CD95L) induces rapid apoptosis of Fas (CD95)-sensitive cells on interaction with Fas, and is an important effector molecule of cytolytic T lymphocytes (CTLs). Melanomas are immunogenic and induce the production of specific CTLs, but are usually able to escape immune destruction. We investigated Fas expression and function in 53 cutaneous melanocytic lesions and 13 melanoma cell lines grown in vitro. Immunohistochemical analysis of Fas expression in cutaneous melanocytic lesions showed moderate to high levels of Fas in common benign melanocytic naevi, but low to undetectable levels in atypical naevi, primary (superficial spreading melanoma, nodular melanoma) and cutaneous melanoma metastases. Fluorescence-activated cell sorting (FACS) analysis of Fas expression in melanoma cell lines revealed undetectable or low levels of cell surface Fas expression in five of the 13 melanoma cell lines. Analysis of Fas signalling by quantification of cell death following exposure to recombinant FasL showed that a reduction in Fas expression results in resistance to FasL-mediated cell death. Furthermore, two of the 13 melanoma cell lines were found to be resistant to FasL-mediated cell death despite conserved Fas expression. Thus seven of the 13 melanoma cell lines were found to have impaired Fas signalling. Taken together, our results indicate that downregulation of Fas expression and resistance to Fas-mediated apoptosis are frequent in melanoma.
R R Bullani; P Wehrli; I Viard-Leveugle; D Rimoldi; J-C Cerottini; J-H Saurat; J Tschopp; L E French
Related Documents :
10894383 - Reactivation of tumor after 19 years? a case of local recurrence in clear cell chondros...
21126163 - Oct4-enhanced green fluorescent protein transgenic pigs: a new large animal model for r...
19268683 - Sea anemone cytolysins as toxic components of immunotoxins.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Melanoma research     Volume:  12     ISSN:  0960-8931     ISO Abbreviation:  Melanoma Res.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-07-25     Completed Date:  2003-01-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  263-70     Citation Subset:  IM    
Department of Dermatology, Geneva University Medical School, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD95 / biosynthesis*,  genetics,  physiology
Apoptosis / drug effects,  genetics*
CASP8 and FADD-Like Apoptosis Regulating Protein
Carrier Proteins / biosynthesis,  genetics
Fas Ligand Protein
Gene Expression Regulation, Neoplastic*
Intracellular Signaling Peptides and Proteins*
Melanocytes / metabolism
Melanoma / genetics,  immunology,  metabolism*,  pathology,  secondary
Membrane Glycoproteins / pharmacology
Neoplasm Proteins / biosynthesis*,  genetics,  physiology
Nevus, Pigmented / genetics,  immunology,  metabolism,  pathology
RNA, Messenger / biosynthesis
RNA, Neoplasm / biosynthesis
Recombinant Proteins / pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Skin Neoplasms / genetics,  immunology,  metabolism*,  pathology
Tumor Cells, Cultured / metabolism
Reg. No./Substance:
0/Antigens, CD95; 0/CASP8 and FADD-Like Apoptosis Regulating Protein; 0/CFLAR protein, human; 0/Carrier Proteins; 0/FASLG protein, human; 0/Fas Ligand Protein; 0/Intracellular Signaling Peptides and Proteins; 0/Membrane Glycoproteins; 0/Neoplasm Proteins; 0/RNA, Messenger; 0/RNA, Neoplasm; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Next Document:  Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and ...